TP53 and metastatic neoplasm: Interestingly, the triple-mutant AKP (APC/KRAS/TP53) group had the highest metastatic rate, with 22% developing metastatic disease from a stage 1–3 primary, suggesting a possible evolution from either AK or AP mutants by adding the third partner mutation.